CIM
RYTM icon

Cambria Investment Management’s Rhythm Pharmaceuticals RYTM Stock Holding History

Cambria Investment Management’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,997
Closed -$214K – 715
2025
Q4 		$214K Buy
+1,997
New +$212K 0.01% 576

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Cambria Investment Management's RYTM Position: Q1 2026 in Review

Cambria Investment Management sold out of Rhythm Pharmaceuticals (RYTM) in Q1 2026, closing a stake of 1,997 shares — an estimated $214K sold.

Cambria Investment Management first reported a position in RYTM in Q4 2025 and held it in 1 quarter. The position peaked at $214K in Q4 2025. 285 funds tracked by Wall St. Rank hold RYTM as of Q1 2026.

  • Cambria Investment Management reported no remaining Rhythm Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Cambria Investment Management sold 1,997 Rhythm Pharmaceuticals shares in Q1 2026, an estimated $214K.
  • Cambria Investment Management first reported a position in Rhythm Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • Cambria Investment Management's Rhythm Pharmaceuticals position peaked at $214K in Q4 2025.
  • 285 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q1 2026.

Based on Cambria Investment Management's 13F filing for Q1 2026, filed 15 May 2026.